


FIGURE 1A

Days Post-Transplant






FIGURE 1R

**Days Post-Transplant**

## Allotransplant Composition

TCD BM +Irrad. SP +20 ug/ml F-SP

months post-BMT 1 2-3 1 2-3




FIGURE 2A

### Allograft Composition

TCD-BM + Irrad SP + 20ug/ml F-SP

months post-BMT 1 2-3 1 2-3 1 2-3




FIGURE 2B

**Splenocytes Administered ( $\times 10^6$ )**

1 Flu.    3 Flu.    10 Flu.    1 Unt.    3 Unt.    8 Unt.




FIGURE 3A




FIGURE 3B




FIGURE 3C

100%  
80%  
60%  
40%  
20%  
0%

Proliferation (% of Control)

Con A  
MLR

0 ug/ml 20 ug/ml



FIGURE 4A

© 1980 "GEMINI"





FIGURE 4B

100%  
90%  
80%  
70%  
60%  
50%  
40%  
30%  
20%  
10%  
0%




### CTL Culture Fludarabine Treatment

FIGURE 4C


**Cells Transplanted into B10.BR**

**BL6 TCD BM + BL6 20ug/ml F-SP + B10.BR SP**

**FIGURE 5**



■ Donor BM ■ Donor SP ■ Recipient



Allograft Composition

FIGURE 6

FIGURE 7A






FIGURE 7B

Days Post-Transplant



SCANNED, #12



FIGURES 8A-B

SCANNED, # 12




FIGURE 9A

SCANNED, # 12




FIGURE 9B

SCANNED, # 12




FIGURE 9C






FIGURE 10



FIGURES 11A-H

FIGURE 12

## Graft Composition



Fluid Rx (no CMV)  
No SP  
SP  
Post Rx (no CMV)